Peptide Romania
cognitive

Semax

ACTH-derived neuropeptide explored for attention, neuroprotection and BDNF expression.

Dovezi
Moderate
T½
Short (intranasal)
Categorie
cognitive
Status
Regional Rx

Evaluarea dovezilor

Baza de dovezi

Moderate66%

Strong: Multiple studii umane controlate cu rezultate consistente și replicate de grupuri independente de cercetare.

Moderate: Studii umane sau animale cu semnale pozitive; există variabilitate metodologică sau date conflictuale limitate.

Emerging: Cercetare timpurie, predominant preclinică, cu rezultate promițătoare. Confirmarea umană este limitată.

Preliminary: Date foarte limitate, în principal rapoarte exploratorii sau studii singulare fără replicare independentă.

Farmacologie

Mecanism de acțiune

ACTH-derived neuropeptide explored for attention, neuroprotection and BDNF expression.

T½Short (intranasal)
StatusRegional Rx
Categoriecognitive
DoveziModerate

Întrebări frecvente

Ce trebuie să știi

ACTH-derived neuropeptide explored for attention, neuroprotection and BDNF expression.
Semax has Moderate evidence. Human or animal studies show positive signals, but some methodological variation or conflicting data exists. Further large-scale trials are needed to confirm findings.
The half-life of Semax is Short (intranasal). This determines dosing frequency in research protocols — shorter half-lives require more frequent administration to maintain stable concentrations in study subjects.
Semax is currently classified as: Regional Rx. Regulatory status varies by jurisdiction — always consult local regulations and a qualified medical professional before any use outside an approved clinical context.
ACTH-derived neuropeptide explored for attention, neuroprotection and BDNF expression.
Înapoi la peptide